NEUROBLASTOMA

This early-phase trial tested whether giving activated natural killer (NK) cells, with or without a protein called rhIL15, is safe and feasible for children and young adults with solid tumors that didn't respond to other treatments. Sixteen participants received chemotherapy to l…

This study tested whether adding the drug bevacizumab (Avastin) to standard chemotherapy helps children with neuroblastoma that has returned or not responded to treatment. The trial enrolled 225 children aged 1 to 21. Researchers looked at tumor shrinkage and how long the disease…

This phase 2 trial tested a combination of a radioactive drug (MIBG), intensive chemotherapy, and a stem cell transplant in 50 children with relapsed or hard-to-treat neuroblastoma. The goal was to see if this approach could shrink tumors and improve survival. The treatment aims …

This early-stage trial tested a radioactive drug called 177Lu-DOTATATE in one child with neuroblastoma that had come back or not responded to standard treatments. The drug targets tumor cells that have a specific marker (somatostatin receptors). The goal was to find a safe dose. …

This early-phase study tested a combination of three oral drugs (irinotecan, temozolomide, and cefixime) in 30 children whose high-risk neuroblastoma had come back or not responded to standard treatment. The goal was to find the safest dose of irinotecan when given with the other…

This early-phase study tested an intravenous form of the drug fenretinide in 17 children whose neuroblastoma had come back or didn't respond to standard treatments. The main goals were to find the safest dose and understand side effects. Researchers also looked at how the drug mo…

This early-phase study tested a new approach for children with neuroblastoma that did not respond to standard treatments. It used two rapid infusions of a radioactive drug (I-MIBG) to target cancer cells, followed by a stem cell transplant to restore healthy blood cells. The goal…

This study tested a new antibody (hu14.18K322A) added to standard chemotherapy for 153 children with high-risk neuroblastoma, a serious nerve tissue cancer. The goal was to see if the combination improves tumor shrinkage and delays the cancer from coming back. While the treatment…

This early-phase study tested a combination of two chemotherapy drugs (irinotecan and vincristine) plus a radioactive drug (131I-MIBG) in 26 children with high-risk neuroblastoma that had come back or not responded to standard treatment. The goal was to find the safest dose of th…

This early-stage trial tested a new oral form of the chemotherapy drug fenretinide in 80 children whose neuroblastoma had come back or resisted standard treatment. The goal was to find the safest dose and understand side effects. Researchers also looked at how the body processes …

This early-phase study tested a new drug called CUDC-907 in 26 children and young adults (ages 1-21) with cancers that had come back or stopped responding to treatment, including solid tumors, brain tumors, and lymphoma. The main goal was to find a safe dose and check for side ef…

This study tested a new way to do stem cell transplants in 23 children with cancers that came back or didn't respond to treatment. The method removes certain immune cells from the donor's stem cells to help the child's body recover faster and fight infections better. The goal was…

This study tested a new treatment for children with high-risk neuroblastoma, a type of cancer. Researchers took the patients' own immune cells (T cells) and modified them to recognize and attack the cancer. Some of these cells were also trained to fight a common virus (EBV) to he…

This study tested whether adding an immunotherapy drug (Hu3F8) plus GM-CSF to standard treatment could help children with high-risk neuroblastoma stay in remission longer. Fifty-nine children who had already achieved remission after initial therapy received the combination along …

This early-phase trial tested a reduced dose of radiation in 78 children with high-risk neuroblastoma. The goal was to see if a lower dose could still control the tumor while causing fewer long-term side effects. Researchers monitored local control rates and side effects over tim…

This early-stage trial tested a drug called lorlatinib in 65 children and young adults with a type of nerve cancer (neuroblastoma) that had come back or not responded to treatment. The drug targets a specific genetic change (ALK) found in their tumors. The study looked at safety,…

This study looked at 119 children who had platinum-based chemotherapy for certain cancers. Researchers wanted to find out if certain genes make some kids more likely to develop hearing loss from the treatment. By analyzing DNA from saliva samples, they hope to identify high-risk …

This study tested whether analyzing the DNA and RNA of a child's tumor could help doctors choose personalized treatments. It included 186 children with relapsed or hard-to-treat cancers like neuroblastoma and brain tumors. The goal was to see if this approach was feasible and saf…